PureTech News

PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

PureTech to Present at Two Upcoming Investor Conferences

PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting

PureTech to Present at CHEST 2024 Annual Meeting

PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults